pharma · Hypertriglyceridemia · Type 2 Diabetes Mellitus · IONS
IONIS PHARMACEUTICALS INC
IONIS PHARMACEUTICALS drug portfolio — 48 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 48 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
IONIS PHARMACEUTICALS drug portfolio — 48 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
US regulatory status: approved.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
US regulatory status: approved.
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Antiinfectives for systemic use (J07) compound in IONIS PHARMACEUTICALS's portfolio.
Blood and blood forming organs (B06) compound in IONIS PHARMACEUTICALS's portfolio.
US regulatory status: approved.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Nervous system (N07) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Transthyretin mRNA.
US regulatory status: approved. Molecular target: Transthyretin mRNA.
US regulatory status: approved. Molecular target: Estrogen receptor.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Sensory organs (S01) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Major intermediate early region 2 mRNA.
US regulatory status: approved. Molecular target: Major intermediate early region 2 mRNA.
Antiinfectives for systemic use (J07) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Surface antigen (HBsAg).
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Nervous system (N07) compound in IONIS PHARMACEUTICALS's portfolio. Mechanism: Transthyretin ANTISENSE inhibitor.
US regulatory status: approved. Molecular target: Transthyretin mRNA.
US regulatory status: approved. Molecular target: Cyclooxygenase.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
US regulatory status: approved. Molecular target: Apo-B 100 mRNA.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Cardiovascular system (C10) compound in IONIS PHARMACEUTICALS's portfolio. Molecular target: Apolipoprotein C-III mRNA.
US regulatory status: approved.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
US regulatory status: approved. Molecular target: Copper.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase 1.
US regulatory status: approved.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Musculo-skeletal system (M09) compound in IONIS PHARMACEUTICALS's portfolio. Mechanism: Somatic cell supplemental therapy.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records.
US regulatory status: approved. Molecular target: SOD1 mRNA.
Cardiovascular system (C10) compound in IONIS PHARMACEUTICALS's portfolio. Mechanism: Apolipoprotein C-III mRNA 3'UTR antisense inhibitor.
Development asset linked to IONIS PHARMACEUTICALS in public FDA and regional records. Mechanism: Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor.
US regulatory status: approved. Molecular target: Vitamin K epoxide reductase complex subunit 1.